NCT01658878 2025-12-24CheckMate040Bristol-Myers SquibbPhase 1/2 Completed657 enrolled 57 charts 3 FDA
NCT03126110 2025-08-14Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic MalignanciesIncyte CorporationPhase 1/2 Completed145 enrolled 47 charts
NCT03222076 2023-07-10Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver CancerM.D. Anderson Cancer CenterPhase 2 Completed30 enrolled 9 charts
NCT03241173 2022-09-27A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic MalignanciesIncyte CorporationPhase 1/2 Completed52 enrolled 25 charts